Research Article Details
| Article ID: | A22377 |
| PMID: | 24630507 |
| Source: | Arab J Gastroenterol |
| Title: | Non alcoholic fatty liver disease (NAFLD) in a Sudanese population: What is the prevalence and risk factors? |
| Abstract: | BACKGROUND AND STUDY AIMS: Non alcoholic fatty liver disease (NAFLD) is a common clinical condition associated with obesity and considered as possible precursor of more serious disease like Non alcoholic steatohepatitis (NASH), cirrhosis and hepatocellular carcinoma. There is very little research work carried concerning NAFLD in African countries in relation to prevalence and risk factors. Therefore, the aim of this study is to determine the prevalence of NAFLD and risk factors among asymptomatic co-patients accompanying patients admitted to gastroenterology wards at the National Centre for GI & Liver Diseases, Ibn Sina Hospital (Khartoum, Sudan). PATIENTS AND METHODS: Subjects with liver disease, excess alcohol intake (the intake of more than 21 units of alcohol per week for men and 14 units for women per week) and pregnancy were excluded from this study. The age, sex, body mass index (BMI), history and duration of diabetes and hypertension were recorded. Ultrasound was offered followed by clinical examination and blood sample was taken for assessment of liver function from each subject (total number of participants was 100). RESULTS: NAFLD was diagnosed in 20 patients, giving prevalence of 20%. There was no statistical significance between the two sexes. The mean age of subjects with NAFLD was 53 years old and without NAFLD was 40 years (p<0.05). Importantly, the prevalence of NAFLD increased with age and BMI. Due to small number of diabetic individuals and hypertension, these two conditions were not statistically significant when related to NAFLD. CONCLUSION: The estimated prevalence of NAFLD in our study is 20% and this figure is comparable to the prevalence of NAFLD in Asian countries. Males and females were nearly equally affected and the prevalence of NAFLD increased with age and BMI, making obesity a main risk factor. |
| DOI: | 10.1016/j.ajg.2014.01.008 |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I12 | 10763 | Hypertension | An artery disease characterized by chronic elevated blood pressure in the arteries. https://en.wikipedia.org/wiki/Hypertension, https://www.ncbi.nlm.nih.gov/pubmed/24352797 | disease of anatomical entity/ cardiovascular system disease/vascular disease/ artery disease | Details |
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| I14 | 9970 | Obesity | An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity | disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D199 | L-alanine | Chemical drug | DB00160 | KYNU | -- | Failed in clinical trials | Details |
| D328 | Serine | Chemical drug | DB00133 | SRR | Improve insulin resistance | Under clinical trials | Details |
| D316 | S-adenosyl-L-methionine | Chemical drug | DB00118 | GNMT cofactor | Antiviral | Under clinical trials | Details |
| D094 | Cysteamine | Chemical drug | DB00847 | GSS stimulant | Renal drug | Under clinical trials | Details |
| D095 | Cysteamine bitartrate | Chemical drug | DB00847 | -- | -- | Under clinical trials | Details |